Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive Officer Gilmore O’Neill said the company has completed its […]